



# Raymed Labs Ltd.

*Manufacturers of Allopathic Medicines*

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

11<sup>th</sup> August, 2014

The Manager  
The Department of Corporate Services  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai - 400001

**BSE Scrip Code: 531207**

**Subject: Outcome of the Meeting of the Board of Directors**

Dear Sir:

This is to inform you that in the meeting of the Board of Directors held on Monday, 11<sup>th</sup> day of August, 2014 at the Registered Office of the Company, following resolutions were passed:

1. The Board considered and approved the Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2014 as per clause 41 of the listing Agreement.
2. The Board took note of the Limited Review as placed by the Auditor of the Company.

You are kindly requested to take the information on record.

Thanking you,

Sincerely,  
**For Raymed Labs Ltd.**

**Ajai Goyal**  
Managing Director  
DIN: 02636418

Encl: as stated

Cc: **Delhi Stock Exchange Limited**  
**Uttar Pradesh Stock Exchange Limited**  
**Ahmedabad Stock Exchange Limited**  
**Jaipur Stock Exchange Limited**

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :


GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

## Unaudited Financial Results for the Quarter Ended on June 30, 2014

PART I							Rs. in Lacs
Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months Ended	Year to Date	Year to Date	Previous Year	
	30-06-2014	31-03-2014	30-06.2013	Figures for Current Period Ended	Figures for the Previous Year Ended	Ended	
	Unaudited	Audited	in the Previous Year	30-06-2014	30-06-2013	31-03-2014	
<b>1 Income from Operations</b>							
(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	-	
(b) Other Operating Income	-	-	-	-	-	-	
<b>Total Income from Operations (net)</b>	-	-	-	-	-	-	
<b>2 Expenses</b>							
(a) Cost of materials consumed	-	-	-	-	-	-	
(b) Purchase of stock-in-trade	-	-	-	-	-	-	
Changes in inventories of finished goods,							
(c) work-in-progress and stock-in-trade	-	-	-	-	-	-	
(d) Employee expenses & benefits	0.45	0.42	0.42	0.45	0.42	1.68	
(e) Depreciation and amortisation expense	-	-0.12	0.31	-	0.31	0.19	
(f) Other expenses	0.23	0.38	0.62	0.23	0.62	1.52	
<b>Total Expenses</b>	<b>0.68</b>	<b>0.68</b>	<b>1.35</b>	<b>0.68</b>	<b>1.35</b>	<b>3.39</b>	
<b>3 Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)</b>	-0.68	-0.68	-1.35	-0.68	-1.35	-3.39	
4 Other Income	0.54	0.54	-	0.54	-	2.13	
<b>5 Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)</b>	-0.14	-0.14	-1.35	-0.14	-1.35	-1.26	
6 Finance Costs	-	-	-	-	-	-	
<b>7 Profit/Loss from ordinary activities after finance costs but before exceptional Items (5-6)</b>	-0.14	-0.14	-1.35	-0.14	-1.35	-1.26	
8 Exceptional Items	-	3.49	-	-	-	3.66	
<b>9 Profit/Loss from Ordinary Activities before tax (7-8)</b>	-0.14	-3.64	-1.35	-0.14	-1.35	-4.92	
10 Tax Expense	-	-	-	-	-	-	
<b>11 Net Profit/ Loss from Ordinary Activities after Tax (9-10)</b>	-0.14	-3.64	-1.35	-0.14	-1.35	-4.92	
12 Extraordinary Item (net of tax expense)	-	-	-	-	-	-	
<b>13 Net Profit/ Loss for the period (11-12)</b>	-0.14	-3.64	-1.35	-0.14	-1.35	-4.92	
17 Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	427.35	
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	
19 I Earning Per Share (before extraordinary items)	-0.003	-0.09	-0.03	-0.003	-0.03	-0.12	
19 II Earning Per Share (after extraordinary items)	-0.003	-0.09	-0.03	-0.003	-0.03	-0.12	



*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART II							
Particulars	3 Months Ended 30-06-2014	Preceding 3 Months Ended 31-03-2014	Corresponding 3 Months Ended 30-06.2013 in the Previous Year	Year to Date Figures for Current Period Ended 30-06-2014	Year to Date Figures for the Previous Year Ended 30-06-2013	Previous Year Ended 31-03-2014	
<b>A PARTICULARS OF SHAREHOLDING</b>							
1 Public Shareholding							
- Number of shares	30,61,450	30,61,450	29,56,450	30,61,450	29,56,450	30,61,450	
- Percentage of shareholding	71.64%	71.64%	69.18%	71.64%	69.18%	71.64%	
2 Promoters and promoter group Shareholding							
a) Pledged/Encumbered							
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil	
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil	
- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil	
b) Non-encumbered							
- Number of Shares	12,12,050	12,12,050	13,17,050	12,12,050	13,17,050	12,12,050	
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	
- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	30.82%	28.36%	30.82%	28.36%	

B INVESTOR COMPLAINTS	3 Months Ended (30/06/2014)
Pending at the beginning of the quarter	NIL
Received during the quarter	NIL
Disposed of during the quarter	NIL
Remaining unresolved at the end of the quarter	NIL

Notes:

- 1 The unaudited financial statements for the quarter ended on June 30, 2014 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2014. The information presented above is extracted from the financial statement.
- 2 EPS has been calculated in accordance with AS-20 issued by ICAI.
- 3 The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by The Institute of Chartered Accountants of India.
- 4 Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- 5 No investor complaints were pending in the beginning and end of the quarter ended June 2014.

For Raymed Labs Limited

*Ajai Goyal*

Ajai Goyal  
Director

Place: Saharanpur  
Date: 11-08-2014

*Life is Precious .....and Raymed cares*